Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis
Authors:
- Wissarut WijitrmektongWWWissarut Wijitrmektong
- Ryan ChoiRCRyan Choi
- Matthew A HulversonMHMatthew A Hulverson
- Lijun LiuLLLijun Liu
- Anne CooperACAnne Cooper
- Kevin P BattaileKBKevin P Battaile
- Elizabeth K HarmonEHElizabeth K Harmon
- Denise Ann DayaoDDDenise Ann Dayao
- Case W McNamaraCMCase W McNamara
- Malina A BakowskiMBMalina A Bakowski
Open Access
- 4 May 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (5) , e1072-e1082
Abstract
Background: Calcium-dependent protein kinase 1 (CDPK1) has emerged as a protozoan-specific target for the treatment of cryptosporidiosis. A previous study identified pyridopyrimidinones as new Cryptosporidium parvum CDPK1 (CpCDPK1) inhibitors with potent growth inhibition against C. parvum and Cryptosporidium hominis. Docking analyses suggested the unique positioning of the kinase's αC-helix could present refinement opportunities. Methods: Compounds designed to optimize the pyridopyrimidinones focused on the back-pocket region predicted to be proximal to the αC-helix, the solvent-exposed region, and the ATP ribose-binding site. Designed derivatives were synthesized and assessed for CpCDPK1 and Src kinase inhibition and for Cryptosporidium spp growth inhibition in mammalian cells. AMP/Mg+2 and 3 inhibitors were cocrystalized with CpCDPK1, and 2 inhibitors were profiled for kinase selectivity. Results: WIN 4-88 was identified with CpCDPK1 (half maximum inhibitory concentration [IC50] = 0.056 μM), and growth inhibition of zoonotic C. parvum NLuc (half maximum effective concentration [EC50] = 0.042 μM), anthroponotic C. parvum Tu114 (EC50 = 0.030 μM), and C. hominis Tu502 (EC50 = 0.062 μM), as well as enhanced kinome selectivity. The crystal structures confirmed the predicted binding mode, indicating key interactions with hinge residue Y155, similar orientations of the solvent-expose moieties, occupancy of the back pocket near the αC-helix, and for 1 inhibitor containing a solubilizing hydroxyethyl attached to the central heterocycle extension into the ATP ribose-binding site. Conclusions: The expanded structure-activity relationship and structural insights will potentially be applicable to other chemotypes with similar binding modes and will enhance development of CpCDPK1 inhibitors for the treatment of cryptosporidiosis.Keywords
Funding Information
- National Institutes of Health (R01AI184396)
- National Institutes of Health (R01AI155412)
- National Institutes of Health (75N93022C00036)
- Wellcome Trust (217812/Z/19/Z)
- U.S. Department of Energy
- Brookhaven National Laboratory (S10OD030394)
This publication has 37 references indexed in Scilit:
- Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for CryptosporidiumMolecular and Biochemical Parasitology, 2024
- Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug DevelopmentACS Infectious Diseases, 2023
- Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signalingEuropean Journal of Medicinal Chemistry, 2021
- Identification and characterization of a new 34 kDa MORN motif-containing sporozoite surface-exposed protein, Cp-P34, unique to CryptosporidiumInternational Journal for Parasitology, 2021
- The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS)The Lancet Global Health, 2019
- Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses studyThe Lancet Global Health, 2018
- Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugsInternational Journal for Parasitology: Drugs and Drug Resistance, 2018
- Discovery and structure activity relationship of the first potent cryptosporidium FIKK kinase inhibitorBioorganic & Medicinal Chemistry, 2017
- A Unique Hexokinase in Cryptosporidium parvum, an Apicomplexan Pathogen Lacking the Krebs Cycle and Oxidative PhosphorylationProtist, 2014
- Differential Functionalization of 1,6‐Naphthyridin‐2(1H)‐ones through Sequential One‐Pot Suzuki–Miyaura Cross‐CouplingsEuropean Journal of Organic Chemistry, 2014